Income tax; modifying credit limit for certain institute in certain tax years. Effective date.
SB301 amends Oklahoma’s income tax credit for donations to certain research organizations. The bill continues the existing credit for taxpayers who donate to an independent biomedical research institute or a cancer research institute, but changes the annual credit caps and how they are calculated beginning in tax year 2026. For tax years through 2025, the total statewide credit cap remains $2 million annually; starting in 2026, the bill splits the cap into $1.5 million for independent biomedical research institutes and $500,000 for cancer research institutes, with the Oklahoma Tax Commission required to adjust the credit percentage each year to stay within those limits.
The bill also revises taxpayer-level limits. For tax year 2026 and later, the credit is limited to $1,000 for single filers and married filing separately, $2,000 for married filing jointly, head of household, and qualifying widow(er) filers, and up to $25,000 for business entities donating to an independent biomedical research institute. It updates the definitions of qualifying institutes, including raising the minimum National Institutes of Health funding threshold for an independent biomedical research institute from $15 million to $20 million and retaining the $4 million National Cancer Institute funding threshold for cancer research institutes. The bill keeps the nonrefundable nature of the credit and the four-year carryforward for unused credits.
In practical terms, SB301 narrows and restructures the state tax expenditure tied to these donations while preserving the incentive for charitable support of biomedical and cancer research. It affects Section 2357.45 of Title 68 and changes who qualifies, how much credit can be claimed, and how much total credit the state will allow each year. The Oklahoma Tax Commission will continue to administer the credit and issue forms, but will now have to apply the new split caps and percentage-adjustment formulas beginning in 2026.
The overall sentiment reflected in the vote history was strongly favorable. The bill passed the Senate 11-0 in committee and 43-0 on third reading, and passed the House 7-1 in committee and 88-0 on third reading, indicating broad bipartisan support. No committee transcripts were provided, so there is no recorded debate to suggest significant opposition in the available materials.
The main point of contention, to the extent one can be inferred from the bill text, is the reallocation and tightening of the credit limits rather than the existence of the credit itself. The bill reduces the overall flexibility of the program by separating the annual cap between the two types of research institutes and by imposing more specific taxpayer caps for 2026 and later. Any concern would likely come from taxpayers, donors, or affected research institutions that may prefer higher or less restrictive credit limits, while supporters likely view the changes as a way to better control the fiscal cost of the incentive and target it more precisely.
SB301 amends 68 O.S. 2021, Section 2357.45, which governs Oklahoma’s income tax credit for donations to independent biomedical research institutes and cancer research institutes. It changes the annual statewide credit limits, taxpayer-level caps, and qualifying-institute definitions, and it directs the Oklahoma Tax Commission to apply new percentage-adjustment formulas beginning in tax year 2026. The bill preserves the credit, keeps it nonrefundable, and maintains the four-year carryforward for unused credits, but it narrows and redistributes the amount of credits that may be claimed each year.
The bill appears to have had overwhelmingly positive reception. It advanced with unanimous or near-unanimous votes in both chambers, including 11-0 in a Senate committee, 43-0 on Senate third reading, 7-1 in a House committee, and 88-0 on House third reading. With no committee transcripts available, there is no evidence of substantial public or legislative controversy in the record provided.
The likely area of disagreement is the bill’s reduction and restructuring of the tax credit program rather than the underlying policy of supporting research donations. SB301 lowers the statewide cap for cancer research credits to $500,000 and sets a separate $1.5 million cap for independent biomedical research credits starting in 2026, while also tightening taxpayer-specific limits and increasing the NIH funding threshold for qualifying biomedical institutes. Potential critics would be donors, research institutions, or advocates who may argue the changes could reduce incentives or funding, while supporters would likely favor the fiscal controls and clearer allocation of credits.